Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms.

J Pediatr Surg

Department of Pediatric Surgery, British Columbia Children's Hospital, Vancouver, British Columbia, Canada V6H 3V4.

Published: December 2008

Purpose: Positron emission tomography/computerized tomography (PET/CT) scan provides both functional and anatomical information in a single diagnostic test. It has the potential to be a valuable tool in the evaluation of pediatric abdominal tumors. The goal of this study is to report our early experience with this technology.

Methods: Children who underwent PET/CT scan in the workup for abdominal neoplasms between July 2005 and January 2008 were identified. Retrospective review of all radiologic studies, operative notes, and pathologic reports was undertaken.

Results: A total of 36 patients were collected. These included Burkitt's lymphoma (8), neuroblastoma (7), rhabdomyosarcoma (6), ovarian tumor (3), Wilms' tumor (2), hepatocellular carcinoma (2), paraganglioma (1), germ cell tumor (1), undifferentiated sarcoma (1), renal primitive neuroectodermal tumor (1), gastrointestinal stromal tumor (1), adrenocortical carcinoma (1), inflammatory pseudotumor (1), and adrenal adenoma (1). All neoplasms were fluorodeoxyglucose (FDG) were avid. Our experience identified several potential uses for PET/CT scan in this group of patients. These include (1) preoperative staging, (2) selection of appropriate site for biopsy, (3) identification of occult metastatic disease, (4) follow-up for residual or recurrent disease, and (5) assessment of response to chemotherapy. It can also be valuable when the standard diagnostic studies are equivocal or conflicting.

Conclusions: Preliminary data indicate that PET/CT is a promising tool in the evaluation of pediatric abdominal malignancies. The delineation of the exact role of this diagnostic modality will require additional experience.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpedsurg.2008.08.064DOI Listing

Publication Analysis

Top Keywords

pet/ct scan
16
evaluation pediatric
12
pediatric abdominal
12
early experience
8
abdominal neoplasms
8
tool evaluation
8
pet/ct
5
tumor
5
experience pet/ct
4
scan
4

Similar Publications

Case report: Detecting giant cell arteritis in [Ga]Ga-DOTA-Siglec-9-PET/CT.

Front Immunol

December 2024

Department of Rheumatology and Clinical Immunology, Clinic of Internal Medicine III, University Hospital Bonn, Bonn, Germany.

Objectives: This study aimed to evaluate the diagnostic utility of [Ga]Ga-DOTA-Siglec-9 positron emission tomography-computed tomography (PET/CT) in assessing disease activity in a patient experiencing a relapse of giant cell arteritis (GCA).

Case Presentation: A 90-year-old male patient with GCA, diagnosed in 2018, was enrolled. Demographic data, disease history, and laboratory parameters, including soluble VAP-1 (sVAP-1) levels, were recorded.

View Article and Find Full Text PDF

Ductal carcinoma (DCIS), a noninvasive breast cancer, rarely metastasises to distant locations. When the initial lesion is stable, bone marrow metastasis (BMM) and bone marrow necrosis (BMN) are even less common. Here, we report the case of a 47-year-old female patient who underwent localized surgery and radiotherapy for right-sided DCIS.

View Article and Find Full Text PDF

Objective: To perform a systematic review and meta-analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV) of the dominant prostatic lesion as measured on preoperative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).

Methods: Prostate-specific membrane antigen PET may offer non-invasive assessment of histopathological and oncological outcomes before definitive treatment. SUV of the dominant lesion has been explored as a prognostic biomarker.

View Article and Find Full Text PDF

Fibroblast activation protein (FAPI) has been recently incorporated as a molecular imaging radiotracer for the evaluation of epithelial neoplasms that support or complement the role of [F]Fluorodeoxyglucose ([F]FDG) in many cancer subtypes since its development. Both radiotracers have been shown to have diagnostic, prognostic, and predictive value for several neoplasms. Herein, we present a 73-year-old male patient with a complex medical and oncological history who was recently diagnosed with hepatocellular carcinoma (HCC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!